Skip to main content

Table 1 Characteristics of included trials

From: Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis

Trial Design Time Region Primary Treatment Median follow-up Sample Median Histology(%) Consolidation Radiotherapy Radiotherapy
   Range   Endpoint   (months) Size Age (SCC/non-SCC) Chemotherapy Dose(Gy) Technology
Liang/2017 [4] III 2007–2011 China OS EP 73 95 59 68.4/31.6 50.5% 60–66 3D
     PC   96 57 64.6/35.4 35.4%   
Wang/2012 [5] II 2004–2007 China OS EP 46 33 55.4 69.7/30.3 75.8% 60–66 3D
     PC   32 60.9 62.5/37.5 59.4%   
Shuayb/2018 [6] II NR Bangladesh NR EP NR 30 NR NR NR 45 NR
     PC   30 NR NR NR   
Bradley/2015 [7] III 2007–2011 USA OS PC-Cet 21 237 64 43/57 67% 60–74 3D
     PC 23 228 64 46/54 67%   
Sugawara/2013 [8] II 2006–2009 Japan ORR UP 20 35 62 42.9/57.1 60% 60 2D − +3D
     NP   31 61 35.5/64.5 58.1%   
Zhao/2016 [9] III 2008–2012 China OS NP 29 48 57.4 67/33 88% 60.6–74.4 3D
     PP   52 60.3 60/40 87%   
Sasaki T/2018 [10] II 2009–2012 Japan OS SP NR 54 60 31.5/68.5 59.3% 60 3D
     NP   54 62 31.5/68.5 44.4%   
Curran Jr./2011 [11] III 1994–1998 USA OS NP 132 195 60 38/62 NR 60 NR
     EP   187 63 37/63 NR   
Oh/2013 [12] III 2005–2007 Korea ORR PC Over 36 33 64 72.7/27.3 63.6% 60–66 3D
     DP   29 61.5 69/31 65.5%   
     GP   31 64 64.5/35.5 64.5%   
Segawa/2010 [13] III 2000–2005 Japan OS MVP NR 101 NR 52.5/37.5 NR 60 2D
     DP   99 NR 44.4/55.6 NR   
Takiguchi/2018 [14] II 2011–2014 Japan OS SP 48 53 NR 26.4/73.6 NR 60 NR
     DP   53 NR 20.8/79.2 NR   
Yamamoto/2010 [15] III 2001–2005 Japan OS MVP NR 146 63 47.9/52.1 41% 60 2D
     IC   147 62 42.2/57.8 29.3%   
     PC   147 63 48.3/51.7 49.7%   
Senan/2016 [16] III 2008–2012 USA OS PP 22 301 59.5 100 76% 60–66 3D
     EP 23 297 58.7 100 74.3%   
Govindan/2011 [17] II 2005–2008 USA OS PP 32 48 65 35/65 69.8% 70 3D
     PP-Cet   53 66 34/66 85.4%   
  1. Abbreviations:OS overall survival, ORR overall response rate, SP S-1-cisplatin, UP UFT-cisplatin, NP vinorelbine-cisplatin, EP etoposide-cisplatin, MVP mitomycin-vindesine-cisplatin, DP docetaxel-cisplatin, PC paclitaxel-cisplatin/carboplatin, PP pemtrexed-cisplatin/carboplatin, IC irinotecan-carboplatin, GP gemcitabine-cisplatin, Cet cetuximab, SCC squamous cell carcinoma, 2D two-dimensional radiotherapy, 3D three-dimensional conformal radiotherapy, NR not reported